Aratana reports 4Q loss

Associated Press |

LEAWOOD, Kan. (AP) _ Aratana Therapeutics Inc. (PETX) on Tuesday reported a loss of $15.6 million in its fourth quarter.

On a per-share basis, the Leawood, Kansas-based company said it had a loss of 37 cents. Losses, adjusted for asset impairment costs, came to 19 cents per share.

The results surpassed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 23 cents per share.

The developer of pet medications posted revenue of $10.5 million in the period, also topping Street forecasts. Three analysts surveyed by Zacks expected $5.7 million.

For the year, the company reported that its loss widened to $47.5 million, or $1.17 per share. Revenue was reported as $25.6 million.

In the final minutes of trading on Tuesday, the company's shares hit $4.43. A year ago, they were trading at $6.95.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on PETX at https://www.zacks.com/ap/PETX

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Comments

Emerging Growth

Radient Technologies Inc.

Radient Technologies Inc is engaged in research, development and commercialization of environmentally responsible technology for the extraction, isolation and purification of soluble products from a wide range of materials using…